Xconomy

NOVEMBER 4, 2019

An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.

San Diego 40

San Diego Study Develop Development 40

Xconomy

OCTOBER 7, 2016

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy. .

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

JULY 15, 2016

Our San Diego editor Bruce Bigelow penned a personal goodbye to entrepreneur Larry Bock, who died last week of pancreatic cancer at the age of 56. After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. The week started on a reflective note.

News 40

News Technical Review San Diego Startup 40

Xconomy

JANUARY 25, 2019

After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.

Guide 63

Guide Patents Startup Develop 63